Pacira BioSciences, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $286.6M | $276.4M | $249.0M | $197.7M | $85.6M | $39.1M | $15.7M | $14.6M |
| Cost of Revenue | $87.9M | $110.1M | $71.8M | $77.4M | $54.8M | $32.1M | $16.7M | $12.3M |
| Gross Profit | $198.7M | $166.3M | $177.2M | $120.2M | $30.8M | $6.9M | $-1.1M | $2.3M |
| Gross Margin | 69.3% | 60.2% | 71.1% | 60.8% | 36.0% | 17.8% | -6.7% | 15.7% |
| Operating Expenses | ||||||||
| Research & Development | $57.3M | $45.7M | $28.7M | $18.7M | $21.6M | $9.9M | $14.9M | $18.6M |
| SG&A Expense | $161.5M | $152.6M | $139.0M | $106.7M | $62.5M | $46.3M | $20.2M | $6.4M |
| Operating Income | $-24.9M | $-32.0M | $9.5M | $-5.2M | $-53.3M | $-49.3M | $-39.1M | $-22.7M |
| Operating Margin | -8.7% | -11.6% | 3.8% | -2.6% | -62.3% | -126.1% | -249.2% | -155.9% |
| Interest Expense | $18.0M | $7.1M | $7.7M | $8.3M | $7.3M | $1.8M | $4.8M | $4.0M |
| Pretax Income | $-42.5M | $-37.8M | $2.1M | $-13.5M | $-64.4M | $-52.3M | $-43.3M | — |
| Income Tax Expense | $140.0K | $105.0K | $264.0K | $173.0K | $-442.0K | $0 | $0 | — |
| Net Income | $-42.6M | $-37.9M | $1.9M | $-13.7M | $-63.9M | $-52.3M | $-43.3M | $-27.1M |
| Net Margin | -14.9% | -13.7% | 0.7% | -6.9% | -74.7% | -133.8% | -276.2% | -186.4% |
| EPS (Basic) | $-1.07 | $-1.02 | $0.05 | $-0.39 | $-1.93 | $-1.72 | $-2.64 | $-47.29 |
| EPS (Diluted) | $-1.07 | $-1.02 | $0.04 | $-0.39 | $-1.93 | $-1.72 | $-2.64 | $-47.29 |
| Shares Outstanding (Basic) | 39.8M | 37.2M | 36.5M | 35.3M | 33.2M | 30.3M | 16.4M | 574.0K |
| Shares Outstanding (Diluted) | 39.8M | 37.2M | 41.3M | 35.3M | 33.2M | 30.3M | 16.4M | 574.1K |
| Dividends Per Share | — | — | — | — | — | — | — | — |